FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine, as global R&D investment approaches $360 billion ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

The Invesco Biotechnology & Genome ETF (PBE) was launched on June 23, 2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the ...

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte (NASDAQ:INCY) and its peers. The biotechnology industry is defined by its ...

This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and ...